Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Gross Profit (2022 - 2025)

Historic Gross Profit for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $503855.0.

  • bioAffinity Technologies' Gross Profit fell 4464.52% to $503855.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 4247.04%. This contributed to the annual value of $3.4 million for FY2024, which is 32679.17% up from last year.
  • As of Q3 2025, bioAffinity Technologies' Gross Profit stood at $503855.0, which was down 4464.52% from $252881.0 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Gross Profit ranged from a high of $989942.0 in Q2 2024 and a low of $834.0 during Q1 2023
  • For the 4-year period, bioAffinity Technologies' Gross Profit averaged around $386926.4, with its median value being $369309.0 (2025).
  • Its Gross Profit has fluctuated over the past 5 years, first surged by 9977410.07% in 2024, then crashed by 7445.5% in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Gross Profit stood at $2171.0 in 2022, then skyrocketed by 25164.72% to $548497.0 in 2023, then increased by 17.67% to $645427.0 in 2024, then fell by 21.93% to $503855.0 in 2025.
  • Its Gross Profit stands at $503855.0 for Q3 2025, versus $252881.0 for Q2 2025 and $485737.0 for Q1 2025.